Dudley, A.C. & Griffioen, A.W., Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis, 2023. doi: 10.1007/s10456-023-09876-7
Griffioen, A.W., et al., Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res, 1996. 56(5): p. 1111-17. PMID: 8640769
Griffioen, A.W., et al., Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood, 1996. 88(2): p. 667-73. PMID: 8695814
Huinen, Z., et al., Anti-angiogenic agents - overcoming tumor endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol., 2021. 18(8): p. 527-540. doi: 10.1038/s41571-021-00496-y
Fukumura, D., et al., Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol, 2018. 15(5): p. 325-340. doi: 10.1038/nrclinonc.2018.29
Dings, R.P., et al., Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res, 2011. 17(10): p. 3134-45. doi: 10.1158/1078-0432.CCR-10-2443
Khan, K.A. and R.S. Kerbel, Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol, 2018. 15(5): p. 310-324. doi: 10.1038/nrclinonc.2018.9
Huijbers, E.J., et al., Tumors resurrect an embryonic vascular gene program to escape immunity. Science Immunol., 2022. 7. doi: 10.1126/sciimmunol.abm6388
springer.com
link.springer.com
Nowak-Sliwinska, P., et al., Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis, 2022. doi: 10.1007/s10456-022-09863-4.
